WO2024009205A1 - STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY - Google Patents
STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY Download PDFInfo
- Publication number
- WO2024009205A1 WO2024009205A1 PCT/IB2023/056889 IB2023056889W WO2024009205A1 WO 2024009205 A1 WO2024009205 A1 WO 2024009205A1 IB 2023056889 W IB2023056889 W IB 2023056889W WO 2024009205 A1 WO2024009205 A1 WO 2024009205A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- antibody
- stable liquid
- liquid pharmaceutical
- histidine
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 36
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 35
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 33
- 239000000872 buffer Substances 0.000 claims abstract description 31
- 239000003381 stabilizer Substances 0.000 claims abstract description 31
- 239000004094 surface-active agent Substances 0.000 claims abstract description 29
- 229930006000 Sucrose Natural products 0.000 claims abstract description 25
- 239000005720 sucrose Substances 0.000 claims abstract description 25
- 125000000185 sucrose group Chemical group 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 88
- 238000009472 formulation Methods 0.000 claims description 81
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- 239000007788 liquid Substances 0.000 claims description 49
- 235000006708 antioxidants Nutrition 0.000 claims description 34
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 30
- 229960002885 histidine Drugs 0.000 claims description 27
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 27
- 229960004452 methionine Drugs 0.000 claims description 25
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 24
- 229930195722 L-methionine Natural products 0.000 claims description 24
- 235000019766 L-Lysine Nutrition 0.000 claims description 22
- 239000004472 Lysine Substances 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 17
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 17
- 229940068968 polysorbate 80 Drugs 0.000 claims description 17
- 229920000053 polysorbate 80 Polymers 0.000 claims description 17
- 229960004914 vedolizumab Drugs 0.000 claims description 12
- 229960003446 histidine monohydrochloride Drugs 0.000 claims description 10
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 8
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 abstract description 4
- 229930182817 methionine Natural products 0.000 abstract description 2
- 239000004067 bulking agent Substances 0.000 abstract 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical group Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 11
- 239000006172 buffering agent Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- -1 histidine ions Chemical class 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- QAWLKTDBUQOFEF-UHFFFAOYSA-N 3-(4-bromophenyl)propanenitrile Chemical compound BrC1=CC=C(CCC#N)C=C1 QAWLKTDBUQOFEF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940127285 new chemical entity Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to a stable liquid formulation of an anti-a4B7 antibody.
- proteins are larger and more complex than traditional organic and inorganic drugs (i.e., possessing multiple functional groups in addition to complex three- dimensional structures), the formulation of such proteins poses special problems.
- a formulation must preserve the conformational integrity of at least a core sequence of the protein's amino acids, while at the same time protecting the protein's multiple functional groups from degradation.
- Proteins may suffer from a lack of stability, and monoclonal and polyclonal antibodies in particular may be relatively unstable. Numerous characteristics may affect a protein's stability. In fact, even in the case of purified antibodies, the antibody structures may be heterogenous, which further complicates the formulation of such systems.
- the excipients included in antibody formulations preferably minimize any potential immune response.
- Degradation pathways for proteins can involve chemical instability (i.e., any process which involves modification of the protein by bond formation or cleavage resulting in a new chemical entity) or physical instability (i.e., changes in the higher order structure of the protein).
- Chemical instability is manifested in, for example, deamidation, isomerization, hydrolysis, oxidation, fragmentation, glycan beta elimination or disulfide exchange.
- Physical instability can result from denaturation, aggregation, precipitation or adsorption, for example.
- the four most common protein degradation pathways are protein fragmentation, aggregation, deamidation, and oxidation.
- Consequences of chemical or physical instability of therapeutic protein include a lowering of the effective administered dose, decreased safety of the therapy due to, for example irritation or immunological reactivity, and more frequent manufacturing due to short shelf life.
- Formulations for each route of administration and dosage forms may be unique and, therefore, have specific requirements.
- Solid dosage forms such as lyophilized powders
- lyophilized powders are generally more stable than liquid (aqueous) formulations.
- reconstitution of the lyophilized formulation requires a significant vial overfill, care in handling and involves high production cost relative to a liquid formulation.
- liquid formulations are advantageous in these and are usually preferred for injectable protein therapeutics (in terms of convenience for the end user and ease of preparation for the manufacturer), this form may not always be feasible given the susceptibility of proteins to denaturation, aggregation and oxidation under stresses such as temperature, pH changes, agitation etc.,. All of these stress factors could result in the loss of biological activity of a therapeutic protein / antibody.
- high concentration liquid formulations are susceptible to degradation and/or aggregation. Nevertheless, high concentration formulations may be desirable for subcutaneous or intravenous route of administration, as the frequency of administration and injection volume is reduced. On the other hand, specific treatment schedule and dosing might require a low concentration formulation and prefer intravenous route of administration for more predictable delivery and complete bioavailability of the therapeutic drug.
- WO2012151247 discloses stable liquid pharmaceutical formulation of Vedolizumab comprising Citrate or EDTA as chelating agent or antioxidant. It further discloses free amino acid which is selected from the group consisting of histidine, alanine, arginine, glycine, glutamic acid and combinations thereof. More particularly, it discloses stable liquid pharmaceutical formulation comprising a mixture of an anti-a4p7 antibody, citrate, histidine, arginine, and polysorbate 80.
- a formulation combination with increased concentration of protein and /or stabilizers may increase the viscosity of the formulation, in turn increasing the injection time and pain at the site of injection and also pose difficulties during processing of the drug substance.
- the main object of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150:1.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
- Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L- methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8..
- Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L-lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50- 220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L-lysine HC1 is in the concentration range of 0-10 mg/mL and L-methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L- lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- the main aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150:1.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L- methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L-lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50- 220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L-lysine HC1 is in the concentration range of 0-10 mg/mL and L-methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L- lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- FIGURE 1 pH trend analysis of RMP & batch 1, 2 & 3 at 40° C.
- FIGURE 2 Percentage HMW (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- FIGURE 3 Percentage purity (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- FIGURE 4 Percentage LMW (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- FIGURE 5 Percentage Acidic (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- FIGURE 6 Percentage Purity (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- FIGURE 7 Percentage Basic (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
- an element means one element or one or more elements.
- compositions are to be interpreted inclusively rather than exclusively.
- Consist are to be interpreted exclusively, rather than inclusively. While various embodiments in the specification are presented using “comprising” language, under other circumstances, a related embodiment is also intended to be interpreted and described using “consisting of or “consisting essentially of’ language.
- pharmaceutical formulation refers to a preparation that contains an anti- a4B7 antibody in such form as to permit the biological activity of the antibody to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- a “stable” formulation is one in which the antibody therein substantially retains its physical stability and/or chemical stability and/or its biological activity upon storage.
- the formulation substantially retains its physical and chemical stability, as well as its biological activity upon storage.
- the storage period is generally selected based on the intended shelf-life of the formulation.
- Various analytical techniques for measuring protein stability are available in the art.
- An antibody "retains its physical stability” in a pharmaceutical formulation if it shows substantially no signs of aggregation, precipitation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography.
- An antibody is said to “retain its chemical stability” in a pharmaceutical formulation when its shows no or minimal formation of product variants which may include variants as a result of chemical modification of antibody of interest such as deamination, oxidation etc.
- Analytical methods such as ion exchange chromatography and hydrophobic ion chromatography may be used to investigate the chemical product variants.
- buffering agent refers to a buffer that resists changes in pH by the action of its acid-base conjugate components.
- the buffering agent may be present in a liquid or solid formulation of the invention.
- the buffering agent of this invention adjusts the pH of the formulation to about 5.8 to 6.8.
- examples of buffering agents that alone or in combination, will control the pH in the 5.8 to 6.8 range include acetate, succinate, gluconate, histidine, citrate, phosphate, maleate, cacodylate, 2-[N- morpholinoj ethanesulfonic acid (MES), bis(2- hydroxyethyl)iminotris[hydroxymethyl]methane (Bis-Tris), N-[2-acetamido]-2- iminodiacetic acid (ADA), glycylglycine and other organic acid buffers.
- the buffering agent herein is histidine.
- a "histidine buffer” is a buffer comprising histidine ions.
- histidine buffers include histidine chloride, histidine acetate, histidine phosphate, histidine sulfate solutions.
- the histidine buffer or histidine-HCl buffer has a between about pH 5.8 to 6.8.
- a “surfactant” herein refers to an agent that lowers surface tension of a liquid.
- the surfactant can be a nonionic surfactant.
- examples of surfactants herein include polysorbate (polyoxyethylene sorbitan monolaurate, for example, polysorbate 20 and, polysorbate 80).
- antioxidant refers to an agent that inhibits the oxidation of other molecules.
- antioxidants herein include L-methionine, lipoic acid, uric acid, glutathione, tocopherol, carotene, lycopene, cysteine, phosphonate compounds, e.g., etidronic acid, desferoxamine and malate.
- an ‘anti-a4B7 antibody’ herein refers to Vedolizumab antibody.
- the main embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150: 1.
- sugar is sucrose.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
- the stable liquid pharmaceutical formulation of anti-a4B7 antibody is high concentration formulation.
- the concentration of anti-a4B7 antibody in the formulation is about 160 mg/ml.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L- lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50-220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L- lysine HC1 is in the concentration range of 0-10 mg/mL and methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L-lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
- the concentration of polysorbate 80 in the formulation of anti-a4B7 antibody is 0.2% w/v.
- the concentration of anti-a4B7 antibody in the formulation is about 160 mg/ml.
- formulation of anti-a4B7 antibody can be administered by subcutaneous route or intravenous route.
- Vedolizumab An anti -a4137 antibody, Vedolizumab, suitable for storage in the present pharmaceutical composition was produced by standard methods known in the art.
- Vedolizumab which was prepared by recombinant expression of immunoglobulin light and heavy chain genes in a mammalian host cell such as Chinese Hamster Ovary cells.
- the expressed Vedolizumab was harvested and the crude harvest was subjected to standard downstream process steps that include purification, filtration and optionally dilution or concentration steps.
- the crude harvest of Vedolizumab may be purified using standard chromatography techniques such as affinity chromatography, ion-exchange chromatography and combinations thereof.
- the purified Vedolizumab solution can additionally be subjected to one or more filtration steps, and the solution obtained was subjected to further formulation studies.
- Vedolizumab formulation was prepared in composition given in the table 1 by dissolving the excipients in water for injection.
- the protein concentration was set to 108 mg/0.68 mL (PFS)/ 158.8 mg/ mL and the pH of the formulation is set to 5.8 to 6.8.
- the Vedolizumab SC formulation drug product was formulated in above mention different buffers and putted on stress stability (40 °C ⁇ 2 °C and 50 °C) and evaluated for analytical techniques as below table 2 and table 3 : Table 2: Stability Study Plan at 40 °C ⁇ 2 °C
- BATCH 4 of formulation F-20 given in table 1 was prepared to assess the real time and accelerated time stability. Following is the result from the real time and accelerated time stability study.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides stable liquid formulation of anti-α4ß7 antibody comprising buffer, bulking agent/ stabilizer, viscosity reducer, antioxidant and surfactant, wherein the bulking agent/ stabilizer is sucrose, viscosity reducer is L-lysine HCl and antioxidant is methionine. The stable liquid formulation according to present invention is suitable for subcutaneous administration.
Description
STABLE LIQUID FORMULATION OF AN ANTI-a4B7 ANTIBODY
RELATED APPLICATIONS
This application is related to Indian Provisional Application IN202221038828 filed 6th Jul, 2022 an is incorporated herein in its entirely.
FIELD OF THE INVENTION
The present invention relates to a stable liquid formulation of an anti-a4B7 antibody.
BACKGROUND OF THE INVENTION
Advances in biotechnology have made it possible to produce a variety of proteins for pharmaceutical applications using recombinant DNA techniques. Because proteins are larger and more complex than traditional organic and inorganic drugs (i.e., possessing multiple functional groups in addition to complex three- dimensional structures), the formulation of such proteins poses special problems. For a protein to remain biologically active, a formulation must preserve the conformational integrity of at least a core sequence of the protein's amino acids, while at the same time protecting the protein's multiple functional groups from degradation. Proteins may suffer from a lack of stability, and monoclonal and polyclonal antibodies in particular may be relatively unstable. Numerous characteristics may affect a protein's stability. In fact, even in the case of purified antibodies, the antibody structures may be heterogenous, which further complicates the formulation of such systems. Moreover, the excipients included in antibody formulations preferably minimize any potential immune response.
In the case of antibodies, preservation of the conformational integrity is even more important. Degradation pathways for proteins can involve chemical instability (i.e., any process which involves modification of the protein by bond formation or cleavage resulting in a new chemical entity) or physical instability (i.e., changes in the higher order structure of the protein). Chemical instability is manifested in, for example, deamidation, isomerization, hydrolysis, oxidation, fragmentation, glycan beta elimination or disulfide exchange. Physical instability can result from denaturation, aggregation, precipitation or adsorption, for example. The four most common protein degradation pathways are protein fragmentation, aggregation, deamidation, and oxidation. Consequences of chemical or physical instability of therapeutic protein include a lowering of the
effective administered dose, decreased safety of the therapy due to, for example irritation or immunological reactivity, and more frequent manufacturing due to short shelf life.
Over the past two decades, recombinant DNA technology has led to the commercialization of many proteins, particularly antibody therapeutics. The effectiveness of these therapeutic antibodies is majorly dependent on the stability, route of administration and their dosage forms and concentrations. This in turn, necessitates therapeutic antibodies to be formulated appropriately to retain the stability and activity of a therapeutic antibody.
Formulations for each route of administration and dosage forms may be unique and, therefore, have specific requirements. Solid dosage forms, such as lyophilized powders, are generally more stable than liquid (aqueous) formulations. However, reconstitution of the lyophilized formulation requires a significant vial overfill, care in handling and involves high production cost relative to a liquid formulation. While liquid formulations are advantageous in these and are usually preferred for injectable protein therapeutics (in terms of convenience for the end user and ease of preparation for the manufacturer), this form may not always be feasible given the susceptibility of proteins to denaturation, aggregation and oxidation under stresses such as temperature, pH changes, agitation etc.,. All of these stress factors could result in the loss of biological activity of a therapeutic protein / antibody. In particular, high concentration liquid formulations are susceptible to degradation and/or aggregation. Nevertheless, high concentration formulations may be desirable for subcutaneous or intravenous route of administration, as the frequency of administration and injection volume is reduced. On the other hand, specific treatment schedule and dosing might require a low concentration formulation and prefer intravenous route of administration for more predictable delivery and complete bioavailability of the therapeutic drug.
Hence, designing a formulation that is stable at high or low concentrations of the therapeutic protein /antibody, aiding in different route of administration (intravenous or subcutaneous), pose a significant developmental challenge. Further, every protein or antibody with its unique characteristics and properties of degradation, adds to the complexity in the development of a stable formulation and may demand a specific formulation.
WO2012151247 discloses stable liquid pharmaceutical formulation of Vedolizumab comprising Citrate or EDTA as chelating agent or antioxidant. It further discloses free amino acid which is selected from the group consisting of histidine, alanine, arginine, glycine, glutamic acid and
combinations thereof. More particularly, it discloses stable liquid pharmaceutical formulation comprising a mixture of an anti-a4p7 antibody, citrate, histidine, arginine, and polysorbate 80.
A formulation combination with increased concentration of protein and /or stabilizers may increase the viscosity of the formulation, in turn increasing the injection time and pain at the site of injection and also pose difficulties during processing of the drug substance. Hence, it is necessary to develop an improved formulation, which contains minimal number or concentration of excipients, yet stabilizing the drug at a wide range of its concentration.
OBJECTS OF THE INVENTION
The main object of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
Another object of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150:1.
Another object of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L- methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8..
Another object of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L-lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50- 220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L-lysine HC1 is in the concentration range of 0-10 mg/mL and L-methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another object of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L- lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
SUMMARY OF THE INVENTION
The main aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150:1.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L- methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L-lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a
concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50- 220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L-lysine HC1 is in the concentration range of 0-10 mg/mL and L-methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another aspect of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L- lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
BRIEF DESCRIPTION OF DRAWING
In order that disclosure may be readily understood and put into practical effect, reference will now be made to exemplary embodiments as illustrated with reference to the accompanying figures. The figures with a detailed description below, are incorporated in and form part of the specification, and serve to further illustrate the embodiments and explains various principles and advantages, in accordance with the present disclosure wherein:
FIGURE 1: pH trend analysis of RMP & batch 1, 2 & 3 at 40° C.
FIGURE 2: Percentage HMW (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
FIGURE 3: Percentage purity (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
FIGURE 4: Percentage LMW (SEC) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
FIGURE 5: Percentage Acidic (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
FIGURE 6: Percentage Purity (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
FIGURE 7: Percentage Basic (CEX) trend analysis of RMP & Batch 1, 2 & 3 at 40° C.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITION
The following definitions are provided to facilitate understanding of certain terms used throughout the specification.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of particular embodiments, preferred embodiments of compositions, methods and materials are described herein. For the purposes of the present disclosure, the following terms are defined below.
The articles "a," "an," and "the" are used herein to refer to one or to more than one (i.e., to at least one, or to one or more) of the grammatical object of the article. By way of example, "an element" means one element or one or more elements.
The words "comprise", "comprises", and "comprising" are to be interpreted inclusively rather than exclusively. The words "consist", "consisting", and its variants, are to be interpreted exclusively, rather than inclusively. While various embodiments in the specification are presented using “comprising” language, under other circumstances, a related embodiment is also intended to be interpreted and described using “consisting of or “consisting essentially of’ language.
The term "pharmaceutical formulation" refers to a preparation that contains an anti- a4B7 antibody in such form as to permit the biological activity of the antibody to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
A "stable" formulation is one in which the antibody therein substantially retains its physical stability and/or chemical stability and/or its biological activity upon storage. In one aspect, the formulation substantially retains its physical and chemical stability, as well as its biological activity upon storage. The storage period is generally selected based on the intended shelf-life of the formulation. Various analytical techniques for measuring protein stability are available in the art.
Stability studies provides evidence of the quality of an antibody under the influence of various environmental factors during the course of time. ICH’s“QlA: Stability Testing of New Drug Substances and Products,” states that data from accelerated stability studies can be used to evaluate the effect of short-term excursions higher or lower than label storage conditions that may occur during the shipping of the antibodies.
Various analytical methods are available for measuring the physical and chemical degradation of the antibody in the pharmaceutical formulations. An antibody "retains its physical stability" in a pharmaceutical formulation if it shows substantially no signs of aggregation, precipitation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography. An antibody is said to “retain its chemical stability” in a pharmaceutical formulation when its shows no or minimal formation of product variants which may include variants as a result of chemical modification of antibody of interest such as deamination, oxidation etc. Analytical methods such as ion exchange chromatography and hydrophobic ion chromatography may be used to investigate the chemical product variants.
As used herein, "buffering agent" refers to a buffer that resists changes in pH by the action of its acid-base conjugate components. The buffering agent may be present in a liquid or solid formulation of the invention. In some embodiments, the buffering agent of this invention adjusts the pH of the formulation to about 5.8 to 6.8. In one aspect, examples of buffering agents that alone or in combination, will control the pH in the 5.8 to 6.8 range include acetate, succinate, gluconate, histidine, citrate, phosphate, maleate, cacodylate, 2-[N- morpholinoj ethanesulfonic acid (MES),
bis(2- hydroxyethyl)iminotris[hydroxymethyl]methane (Bis-Tris), N-[2-acetamido]-2- iminodiacetic acid (ADA), glycylglycine and other organic acid buffers. In another aspect, the buffering agent herein is histidine.
A "histidine buffer" is a buffer comprising histidine ions. Examples of histidine buffers include histidine chloride, histidine acetate, histidine phosphate, histidine sulfate solutions. The histidine buffer or histidine-HCl buffer has a between about pH 5.8 to 6.8.
A "surfactant" herein refers to an agent that lowers surface tension of a liquid. The surfactant can be a nonionic surfactant. In one aspect, examples of surfactants herein include polysorbate (polyoxyethylene sorbitan monolaurate, for example, polysorbate 20 and, polysorbate 80).
An "antioxidant" herein refers to an agent that inhibits the oxidation of other molecules. Examples of antioxidants herein include L-methionine, lipoic acid, uric acid, glutathione, tocopherol, carotene, lycopene, cysteine, phosphonate compounds, e.g., etidronic acid, desferoxamine and malate.
An ‘anti-a4B7 antibody’ herein refers to Vedolizumab antibody.
The main embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising a mixture of an anti-a4B7 antibody, a buffer, stabilizer, antioxidant, viscosity reducer and surfactant.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising anti-a4B7 antibody, a buffer, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, sugar, viscosity reducer, antioxidant and surfactant at pH about 5.8 to 6.8, wherein the molar ratio of sugar to anti-a4p7 antibody (mole:mole) is less than 150: 1.
In another embodiment of the present invention sugar is sucrose.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation comprising at least about 50 mg/ml to about 220 mg/ml anti-a4B7 antibody, a buffering agent, stabilizer, L-methionine as an antioxidant, L-lysine HC1 as a viscosity reducer and surfactant.
In another embodiment of the present invention, the stable liquid pharmaceutical formulation of anti-a4B7 antibody is high concentration formulation.
In another embodiment of the present invention, the concentration of anti-a4B7 antibody in the formulation is about 160 mg/ml.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising a buffer, stabilizer, viscosity reducer, antioxidant and surfactant, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a viscosity reducer and L-methionine as an antioxidant, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising L-histidine, L-histidine monohydrochloride, sucrose, L- lysine HC1, L-methionine and polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising buffer, stabilizer, viscosity reducer, antioxidant and surfactant; wherein the anti-a4B7 antibody is at a concentration of about 50-220 mg/mL, buffer is at a concentration range of 0-100 mM, stabilizer is at a concentration range of 0-100 mg/mL, viscosity reducer is at a concentration range of 0-10 mg/mL, antioxidant is at a concentration range of 0-2 mg/mL and surfactant is at a concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising sucrose as a stabilizer, L-lysine HC1 as a
viscosity reducer and L-methionine as an antioxidant; wherein the anti-a4B7 antibody is at concentration of about 50-220 mg/mL, sucrose is in the concentration range of 0-100 mg/mL, L- lysine HC1 is in the concentration range of 0-10 mg/mL and methionine is in the concentration range of 0-2 mg/mL, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 0-100 mM histidine/histidine monohydrochloride, 0-100 mg/mL sucrose, 0-10 mg/mL L-lysine HC1, 0-2 mg/mL L-methionine and 0-2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
Another embodiment of the present invention is to provide stable liquid pharmaceutical formulation of an anti-a4B7 antibody comprising 50 mM histidine/histidine HC1, 45 mg/mL sucrose, 8 mg/mL L-lysine HC1, 1.49 mg/mL L-methionine and 2 mg/mL polysorbate 80, wherein the formulation has pH about 5.8 to 6.8.
In another embodiment of the present invention the concentration of polysorbate 80 in the formulation of anti-a4B7 antibody is 0.2% w/v.
In another embodiment of the present invention the concentration of anti-a4B7 antibody in the formulation is about 160 mg/ml.
In another embodiment of the present invention formulation of anti-a4B7 antibody can be administered by subcutaneous route or intravenous route.
The embodiments of the present invention are further described using specific examples herein after. The examples are provided for better understanding of certain embodiments of the invention and not, in any manner, to limit the scope thereof. Possible modifications and equivalents apparent to those skilled in the art using the teachings of the present description and the general art in the field of the invention shall also from the part of this specification and are intended to be included within the scope of it.
EXAMPLES:
EXAMPLE 1: SCREENING OF FORMULATION EXCIPIENTS
An anti -a4137 antibody, Vedolizumab, suitable for storage in the present pharmaceutical composition was produced by standard methods known in the art. For example, Vedolizumab which was prepared by recombinant expression of immunoglobulin light and heavy chain genes in a mammalian host cell such as Chinese Hamster Ovary cells. Further, the expressed Vedolizumab was harvested and the crude harvest was subjected to standard downstream process steps that include purification, filtration and optionally dilution or concentration steps. For example, the crude harvest of Vedolizumab may be purified using standard chromatography techniques such as affinity chromatography, ion-exchange chromatography and combinations thereof. The purified Vedolizumab solution can additionally be subjected to one or more filtration steps, and the solution obtained was subjected to further formulation studies.
Method of preparation: Vedolizumab formulation was prepared in composition given in the table 1 by dissolving the excipients in water for injection. The protein concentration was set to 108 mg/0.68 mL (PFS)/ 158.8 mg/ mL and the pH of the formulation is set to 5.8 to 6.8.
0.68 mL of drug product solution was filled in 1 mL Syringe barrel-USP type I siliconized and stopper them with plunger stopper and store the filled PFS in between 2° C and 8° C.
Different excipients with different concentration were tested. Total 22 formulations were prepared with different concentration of excipients as shown in below table 1.
The Vedolizumab SC formulation drug product was formulated in above mention different buffers and putted on stress stability (40 °C ± 2 °C and 50 °C) and evaluated for analytical techniques as below table 2 and table 3 :
Table 2: Stability Study Plan at 40 °C ± 2 °C
EXAMPLE2: STRESS STABILITY STUDY
A) Physical appearance:
All the samples were observed to be colorless to yellow solution
Observation: Based on 7 days stress data the pH of the most of formulation were comparable with the reference formulation (RMP).
C) Protein Concentration:
MA: Not analyzed
Observation: Based on 7 days stress data the Protein concentration of most of formulations were comparable with the reference formulation (RMP)
D) CEX- HPLC
Observation: Based on 7 days stress data, for % acidic of the F-10, F-20, F-21, F-22, and F-35 to F39 were comparable with the reference formulation (RMP);
For % Purity of the F-20, F-22 to F-29 and F-35 to F-39 were comparable with the reference formulation (RMP); and
For % Basic of the F-20, F-24 to F 31, F-35, F-37 & F-38 were comparable with the reference formulation (RMP).
E) SEC- HPLC
Observation: Based on 7 days stress data the SEC data (% Basic) of the F10, F-20, F-35, F-37 & F-38 was comparable with the reference formulation (RMP); and
For % HMW of the F10, F-20, F-35, F-37 & F-38 was comparable with the reference formulation (RMP).
From the result of the above study, Formulation 20 (F-20) shown closer degradation compare to
RMP.
EXAMPLE 3: STRESS STABILITY STUDY AT 40° C
Three different consistency batches BATCH 1, BATCH 2, and BATCH 3 of formulation F-20 given in table 1 was prepared to assess the stress stability. Following is the result from the stress stability study at 40° C.
A) Physical appearance:
All the samples were observed to be Colourless to yellow solution
B) pH:
Observation: Based on 28 days Stress stability data the pH of all the 3 batches was comparable with the reference formulation (RMP) as depicted in Figure 1.
C) SEC- HPLC
Observation: Based on 28 days Stress stability data the SEC- HPLC of all the 3 batches was comparable with the reference formulation (RMP) as depicted in Figure 2, 3 & 4.
D) CEX- HPLC
Table 10: CEX data of Stress Stability (40 °C)
Observation: Based on 28 days Stress stability data the CEX- HPLC of all the 3 batches was comparable with the reference formulation (RMP) as depicted in Figure 5, 6 & 7.
EXAMPLE 4; REAL TIME (2° C -8° C) AND ACCELARATED TIME (25° C) DATA OF
BATCH 4.
BATCH 4 of formulation F-20 given in table 1 was prepared to assess the real time and accelerated time stability. Following is the result from the real time and accelerated time stability study.
A. Physical appearance:
All the samples were observed to be Colourless to yellow solution
B. pH:
C. Protein Concentration:
E. CEX- HPLC
Result of the above study indicated that there is no change between formulation F-20 of present invention and RMP formulation. This means that formulation of present invention is highly comparable with the RMP formulation.
Claims
1. A stable liquid pharmaceutical formulation comprising: anti-a4p7 antibody, buffer, stabilizer, anti-oxidant, viscosity reducer and surfactant.
2. The stable liquid pharmaceutical formulation of claim 1, wherein buffer is Histidine/ histidine monohydrochloride, having concentration of 0-100 mM, more preferably about 50 mM.
3. The stable liquid pharmaceutical formulation of claim 1, wherein stabilizer is sucrose, having concentration of 0-100 mg/ml, more preferably about 45 mg/ml.
4. The stable liquid pharmaceutical formulation of claim 1, wherein anti-oxidant is L- methionine, having concentration of 0-2 mg/ml, more preferably about 1.49 mg/ml.
5. The stable liquid pharmaceutical formulation of claim 1, wherein viscosity reducer is L- lysine HC1, having concentration of 0-10 mg/ml, more preferably about 8 mg/ml.
6. The stable liquid pharmaceutical formulation of claim 1 , wherein surfactant is polysorbate 80, having concentration of 0-2 mg/ml, more preferably about 2 mg/ml.
7. A stable liquid pharmaceutical formulation of Vedolizumab comprising: Histidine/ histidine monohydrochloride as buffer, sucrose as stabilizer, L- lysine HC1 as viscosity reducer, L- methionine as anti-oxidant, polysorbate 80 as surfactant, wherein the formulation has the molar ratio of sugar to anti-a4p7 antibody (mole:mole) less than 150:1.
8. The stable liquid pharmaceutical formulation of claim 7, wherein the formulation comprises: 0-100 mM histidine/ histidine monohydrochloride, 0-100 mg/ml sucrose, 0-10 mg/ml L-lysine HC1, 0-2 mg/ml L-methionine and 0-2 mg/ml polysorbate 80, wherein pH of formulation is about 5.8 to 6.8.
9. The stable liquid pharmaceutical formulation of claim 7, wherein the formulation comprises: 160 mg/ml Vedolizumab, 50 mM histidine/ histidine HC1, 45 mg/ml sucrose, 8 mg/ml L-lysine HC1, 1.49 mg/ml L-methionine, and 2 mg/ml polysorbate 80, at pH 5.8 to 6.8.
10. A stable liquid pharmaceutical formulation of 160 mg/ml Vedolizumab comprising: 50 mM Histidine/ histidine monohydrochloride as buffer, 45 mg/ml sucrose as stabilizer, 8 mg/ml L- lysine HC1 as viscosity reducer, 1.49 mg/ml L- methionine as anti-oxidant, 2
mg/ml polysorbate 80 as surfactant, wherein the formulation has the molar ratio of sugar to anti-a4p7 antibody (mole:mole) less than 150:1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202221038828 | 2022-07-06 | ||
IN202221038828 | 2022-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024009205A1 true WO2024009205A1 (en) | 2024-01-11 |
Family
ID=89454472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/056889 WO2024009205A1 (en) | 2022-07-06 | 2023-07-03 | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024009205A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017031288A1 (en) * | 2015-08-19 | 2017-02-23 | Medimmune, Llc | Stable anti-ifnar1 formulation |
WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2023
- 2023-07-03 WO PCT/IB2023/056889 patent/WO2024009205A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017031288A1 (en) * | 2015-08-19 | 2017-02-23 | Medimmune, Llc | Stable anti-ifnar1 formulation |
WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10925931B2 (en) | Rapid-acting insulin compositions | |
EP3212667B1 (en) | Pharmaceutical anti-tnf-alpha antibody formulation | |
US20210401982A1 (en) | Stable formulations of therapeutic antibody | |
US20210147555A1 (en) | Antibody formulation | |
CN106729627B (en) | Recombinant human erythropoietin preparation | |
WO2024009205A1 (en) | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY | |
US20230340131A1 (en) | Stable aqueous high concentration formulation of integrin antibody | |
US20240084016A1 (en) | Stable formulation of integrin antibody | |
US20240101679A1 (en) | Stable aqueous buffer free formulation of an integrin antibody | |
CA3234358A1 (en) | Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody | |
WO2024023843A1 (en) | A pharmaceutical formulation of a therapeuticantibody and preparations thereof | |
WO2023037384A1 (en) | Formulations of immune check point inhibitors or like | |
US20210253714A1 (en) | Stable antibody formulation | |
US20240101659A1 (en) | Stable therapeutic protein formulation and methods of making the same | |
EP3287141B1 (en) | Nerve growth factor composition and injection powder | |
WO2023037383A1 (en) | Formulations of immune check point inhibitors | |
WO2023031970A1 (en) | A pharmaceutical formulation of immune check point inhibitors | |
US20160095904A1 (en) | Stabilized liquid formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23835023 Country of ref document: EP Kind code of ref document: A1 |